Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alpha Cognition Inc.ACOG · Entity 6339 | VP Finance and Accounting | January 09, 2026 | January 14, 2026 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alpha Cognition Inc.
Report date January 09, 2026 · Filed January 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 20,579 |
Reported balance
After 2026-01-09 transaction · row 1
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 20,579 · Balance 20,579 F1: Restricted stock units that vest on 1/3 on January 9, 2027, 1/3 on January 9, 2028 and 1/3 on January 9, 2029. |
| Common Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.56 · Expires 2036-01-09 | Direct | 15,982 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 15,982 · Balance 15,982 F2: The options will vest 1/3 on January 9, 2027 and the remainder to vest in equal installments quarterly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest on 1/3 on January 9, 2027, 1/3 on January 9, 2028 and 1/3 on January 9, 2029.
F2: The options will vest 1/3 on January 9, 2027 and the remainder to vest in equal installments quarterly thereafter.
Emmaus Life Sciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 14, 2026 01:17 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Share Options · Derivative | 15,982 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000912282-26-000033 · form4.xml · derivative · entry 2 DU HENRY HUY · CIK 0002044763 · VP Finance and Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,982 Underlying: Common Shares · 15,982 shares Expires 2036-01-09 F2 · derivative.exercise_date: The options will vest 1/3 on January 9, 2027 and the remainder to vest in equal installments quarterly thereafter. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 01:17 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Shares | 20,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000033 · form4.xml · nonDerivative · entry 1 DU HENRY HUY · CIK 0002044763 · VP Finance and Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,579 F1 · shares: Restricted stock units that vest on 1/3 on January 9, 2027, 1/3 on January 9, 2028 and 1/3 on January 9, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.